Unknown

Dataset Information

0

A combination of extracellular matrix- and interferon-associated signatures identifies high-grade breast cancers with poor prognosis.


ABSTRACT: Breast cancer (BC) is a heterogeneous disease in which the tumor microenvironment (TME) seems to impact the clinical outcome. Here, we investigated whether a combination of gene expression signatures relating to both the structural and immune TME aspects can help predict prognosis in women with high-grade BC (HGBC). Thus, we focused on a combined molecular biomarker variable that involved extracellular matrix (ECM)-associated gene expression (ECM3 signature) and interferon (IFN)-associated metagene (IFN metagene) expression. In 97 chemo-naive HGBCs from the METABRIC dataset, the dichotomous ECM3/IFN (dECIF) variable identified a group of high-risk patients (ECM3+ /IFN- vs other; hazard ratio = 3.2, 95% confidence interval: 1.5-6.7). Notably, ECM3+ /IFN- tumors showed low tumor-infiltrating lymphocytes, high levels of CD33-positive cells, absence of PD-1 expression, or low expression of PD-L1, as suggested by immune profiles and immune-histochemical analysis on an independent cohort of 131 HGBCs. To make our results transferable to clinical use, we refined the dECIF biomarker using reduced ECM3 and IFN signatures; notably, the prognostic value of this reduced dECIF was comparable to that of the original dECIF. After validation in a new BC cohort, reduced dECIF was translated into a robust qPCR classifier for real-world clinical use.

SUBMITTER: Lecchi M 

PROVIDER: S-EPMC8096783 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC9381844 | biostudies-literature
| S-EPMC4223627 | biostudies-literature
| S-ECPF-GEOD-42948 | biostudies-other
2012-10-11 | E-GEOD-40222 | biostudies-arrayexpress
| S-EPMC8624456 | biostudies-literature
| S-EPMC10523239 | biostudies-literature
| S-EPMC3109576 | biostudies-literature
2023-12-11 | GSE249935 | GEO
| S-EPMC3794716 | biostudies-literature
2012-10-11 | GSE40222 | GEO